

# Lu Ping Tan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6192330/publications.pdf>

Version: 2024-02-01

23  
papers

997  
citations

687363

13  
h-index

752698

20  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2050  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. <i>BMC Cancer</i> , 2009, 9, 163.	2.6	190
2	Hodgkin Lymphoma Cell Lines Are Characterized by a Specific miRNA Expression Profile. <i>Neoplasia</i> , 2009, 11, 167-IN9.	5.3	133
3	miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high miR-155 expression. <i>Journal of Pathology</i> , 2008, 215, 13-20.	4.5	109
4	A high throughput experimental approach to identify miRNA targets in human cells. <i>Nucleic Acids Research</i> , 2009, 37, e137-e137.	14.5	105
5	miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. <i>Laboratory Investigation</i> , 2009, 89, 708-716.	3.7	103
6	Evaluation of extraction kits and RT-qPCR systems adapted to high-throughput platform for circulating miRNAs. <i>Scientific Reports</i> , 2015, 5, 9430.	3.3	60
7	Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2336-2347.	5.1	53
8	HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. <i>International Journal of Cancer</i> , 2015, 136, 678-687.	5.1	48
9	A High Throughput Experimental Approach to Identify miRNA Target Genes in Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 1461-1461.	1.4	42
10	The Microenvironment in Epstein-Barr Virus-Associated Malignancies. <i>Pathogens</i> , 2018, 7, 40.	2.8	40
11	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. <i>Scientific Reports</i> , 2017, 7, 42980.	3.3	27
12	Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line. <i>Cancer Cell International</i> , 2014, 14, 101.	4.1	15
13	CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2017, 7, 12372.	3.3	15
14	A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2260-2266.	5.1	12
15	No difference in the occurrence of mismatch repair defects and APC and CTNNB1 genes mutation in a multi-racial colorectal carcinoma patient cohort. <i>Pathology</i> , 2007, 39, 228-234.	0.6	10
16	Identification and characterization of a novel Epstein-Barr Virus-encoded circular RNA from LMP-2 Gene. <i>Scientific Reports</i> , 2021, 11, 14392.	3.3	10
17	Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2021, 504, 81-90.	7.2	9
18	Integrated pathway analysis of nasopharyngeal carcinoma implicates the axonemal dynein complex in the Malaysian cohort. <i>International Journal of Cancer</i> , 2016, 139, 1731-1739.	5.1	8

#	ARTICLE	IF	CITATIONS
19	High-Throughput RT-qPCR for the Analysis of Circulating MicroRNAs. <i>Methods in Molecular Biology</i> , 2017, 1580, 7-19.	0.9	7
20	Specific Micro-RNA Expression Profile in Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 381-381.	1.4	0
21	miRNA Profiling of B Cell Subsets: Specific miRNA Profile for Germinal Center B Cells with a Marked Variation Between Centroblast and Centrocytes.. <i>Blood</i> , 2008, 112, 1459-1459.	1.4	0
22	Repression of Mir-106b Family Members Does Not Alter Cell Cycle Progression in Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 4722-4722.	1.4	0
23	Nasopharyngeal carcinoma in adolescent patients: A case series. <i>Clinical Otolaryngology</i> , 2022, 47, 486-490.	1.2	0